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liver injury in developed countries and China. Chronic systemic inflammation plays a decisive
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risk nonalcoholic steatohepatitis (NASH) states. However, the exact mechanisms by which
inflammation leading to NASH are incompletely understood. In this review, we focus the role
of the cross talk between inflammation and lipid homeostasis on the progression of NAFLD.
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ing Medical University. ProductionNAFLD has become the leading cause of chronic liver injury
in developed countries. The prevalence of NAFLD among
adults in the general population is approximately 15%
(6.3e27.0%) in China.1 NAFLD is strongly associated with
obesity, insulin resistance, hypertension, and dyslipidemia,
suggesting that NAFLD might be considered as the liver
manifestation of the metabolic syndrome.
NAFLD, characterized by increased lipids accumulation
(mainly triglycerides and cholesterol) in the liver repre-
sents a spectrum of disease ranging from “simple steatosis”
(SS), which is considered relatively benign, to nonalcoholic
steatohepatitis (NASH) and to NAFLD-associated cirrhosis
and end-stage liver disease. SS is believed to be the basis
for the development of NASH. However, only 10e20% of
patients with SS develop to NASH, which can progress toand hosting by Elsevier B.V. All rights reserved.
Inflammation, lipid metabolic disorder and NAFLD 107cirrhosis, end-stage liver disease, and hepatocellular car-
cinoma.2 Why not all NAFLD patients progressed to NASH is
largely unknown.
The “two-hit hypothesis” has become an important
theoretical framework for understanding NAFLD pathogen-
esis.3 The first hit mainly consists of lipid accumulation in
the liver in the form of triglycerides and free fatty acids
accompanied by small amounts of cholesterol, cholesterol
ester, and phospholipid, a process that is closely linked with
SS and insulin resistance.4 The second hit involves an in-
flammatory insult to the liver. The cytokines or chemokines
released by hepatocytes or activated neutrophils further
exacerbate hepatic tissue injuries induced by the first hit
and cause NASH.5 However, this theory has been put into
question based on insights on the interaction between lipid
homeostasis, insulin resistance, and inflammatory stress. It
is now appreciated that a more complex process including
lipotoxicity, insulin resistance, oxidative stress and in-
flammatory cascade is probably responsible for liver injury
and promote NAFLD progression. The “multiple-parallel-
hit” hypothesis has arisen.6
Chronic systemic inflammation plays a decisive role and
is fundamental in the progression of NAFLD from SS toward
higher risk cirrhotic states.7 However, the exact mecha-
nisms by which inflammation leading to NASH are incom-
pletely understood. In this review, we focus the role of the
cross talk between inflammation and lipid homeostasis on
the progression of NAFLD.The role of inflammation in NAFLD
Hepatic steatosis is the common feature of NAFLD from
early stage to advanced NASH-cirrhosis. The pathogenesis
of NASH was originally conceptualised as a disease of
consecutive hits: the accumulation of fat in the liver cells
(steatosis), cascade of inflammation, fibrosis and cirrhosis.
The lipotoxicity of hepatic fat induces inflammatory stress
and oxidative stress.8 Many studies have found that in-
flammatory stress is involved in the occurrence and devel-
opment of NAFLD process, not only at the process of the
second hit, suggesting that both inflammation and lipid are
important risk factors for hepatic steatosis. NAFLD has been
regarded as an inflammatory disorder, which is character-
ized by low-grade chronic systemic inflammation,9 under-
scoring the similarities between NAFLD and the metabolic
syndrome.10,11 Circulating concentrations of C-reactive
protein (CRP) and pro-inflammatory cytokines, such as
tumor necrosis factor alpha (TNF-a) and interleukin-6 (IL-6)
are considered to be the most important factors in causing
and maintaining insulin resistance12 and closely related to
the development of NAFLD and other metabolic disorders.13
TNF-a and IL-6 expression in liver is strongly induced in
response to high fat diet and inhibition of TNF and IL-6
signaling prevents hepatic steatosis without a consider-
able effect on weight gain. Elevated serum TNF-a level is
associated with the development of NAFLD and an inde-
pendent factor for NASH in a clinical human study.14
Recently, mice treated with the anti-TNF-a drug thalido-
mide show some improvements in the hepatic alterations
mediated by a high-fat diet.15 In a rat experimental model
of NASH, anti-TNF-a antibodies decrease inflammation,necrosis, and fibrosis.16 Moreover, several studies have
shown that inflammatory cytokines increase serum free
fatty acids (FFA) levels, causing dyslipidemia and NAFLD,
which can be prevented by using anti-cytokine antibodies in
mouse models.17,18
IL-6 is a key element in the acute phase response,
mediating the synthesis of several acute phase proteins
(such as CRP and serum amyloid A).19 It also plays an indi-
rect deleterious role in NAFLD pathogenesis. Serum IL-6
levels are higher in animal models and patients with
NAFLD.9,20,21 Diet-induced NASH is reduced in IL-6 knockout
mice.22 In humans with NASH, a positive correlation be-
tween IL-6 expression in hepatocytes and the severity of
NAFLD was observed.23
Although many cytokines are shown to modulate the
progression of NAFLD, the central mechanism that mediates
the effects of these cytokines on the progression of NAFLD,
are not fully clear. Nonetheless, several specific intracel-
lular signaling pathways, including nuclear factor NF-kB,
Jun kinases (JNK), activating protein-1 (AP-1), STAT3,
AMPK-TORC1 pathway have emerged as potential targets
for many of these cytokines and chemokines.24
Among the inducible transcription factors that control
inflammatory gene expression, NF-kB plays a central and
evolutionarily conserved role in coordinating the expression
of various soluble pro-inflammatorymediators and leukocyte
adhesion molecules. NF-kB is a collection of protein dimers
that control the transcription of a host of target genes. NF-kB
dimers aremainly kept inactive through binding to inhibitory
proteins IkB. The IkB kinase (IKK) complex, which is respon-
sive to many inflammatory stimuli, phosphorylates the IkBs,
thereby triggering their degradation, and causing NF-kB
activation. Recent data lend credence to the fact that he-
patic steatosis activates IKK and NF-kB.20 The degradation of
IkB thus allows NF-kB to translocate into the nucleuswhere it
can act as a transcription factor that upregulates IL-6 pro-
duction and secretion. It has been demonstrated that high
fat diet increases NF-kB activation, resulting in a sustained
elevation of the IKK-related kinase IKKε in liver. IKKε ablation
reduces expression of inflammatory cytokines and protects
mice from high-fat diet-induced obesity, chronic inflamma-
tion in liver and adipose tissue, and hepatic steatosis.25 In
addition, JNK activation increases production of inflamma-
tory cytokines capable.26 The two main isoforms of JNK
(JNK1 and JNK2) appear to have distinct specific effects on
murine NASH. JNK1 promotes steatosis and hepatitis while
JNK2 inhibits hepatocyte cell death.27 These results suggest
that chronic low-grade systemic inflammation play a key role
on the progression from hepatic steatosis to NASH, fibrosis,
cirrhosis.24Effects of inflammation on FFA uptake, synthase
and oxidation in the liver
NAFLD is a consequence of excessive lipids accumulation in
liver. Hepatic triglycerides (TG) and FFA accumulation results
from an imbalance between lipid availability from circulating
lipid uptake or de novo lipogenesis (DNL) and lipid disposal via
FFA b-oxidation or TG-rich lipoprotein secretion. Excessive
intrahepatic TG or steatosis generally occurs when there is
more fatty acid synthesis and less fatty acid oxidation. This
108 Y. Chen et al.eventually triggers lipoperoxidative stress and hepatic injury.
Studies on obese adults with hepatic steatosis have described
an increased hepatic de novo lipogenesis accompaniedwith a
decreased fatty acid oxidation.28e30 In normal subjects, de
novo lipogenesis contributes to less than 5% of fatty acid
incorporated into secreted VLDL-TG. However, the rate of de
novo fatty acid synthesis is greatly increased and accounts for
approximately 20% of the fatty acid in intrahepatic TG in
subjects with NAFLD.31,32 Moreover, inhibition or activation
of intrahepatic fatty acid oxidation can influence intra-
hepatic TG content. Genetic or experimentally-induced de-
ficiencies inmitochondrial oxidative enzymes lead to hepatic
steatosis,33e35 whereas increasing the expression or activity
of hepatic enzymes involved in fatty acid oxidation, reduces
intrahepatic TG accumulation in rodent animal models.36,37
This suggests that the balance between fatty acid produc-
tion and consumption plays an important role in maintaining
normal intrahepatic TG levels.
Inflammation may modify hepatic lipid homeostasis,
thereby enhancing lipid accumulation in the liver. There
are several key transcription factors and enzymes regu-
lating intrahepatic fatty acids synthesis and oxidation.
Sterol regulatory element-binding protein-1,2 (SREBP-1,2)
are nuclear transcription factors that transcriptionally
activate genes involved in de novo lipogenesis.38,39 The
acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS)
are important downstream target genes of SREBP-1, which
are the rate-limiting enzymes of palmitate molecule for-
mation. Moreover, carnitine palmitoyltransferase 1A
(CPT1A), hydroxyacyl-CoA dehydrogenase beta subunit
(HADHB) and carnitine O-octanoyltransferase (CROT) are
key enzymes of intrahepatocellular fatty acid oxidation,
which mediate the transport of long-chain fatty acids inside
the mitochondrial matrix, catalyze mitochondrial b-oxida-
tion to liberate carbon units and catabolize very long-chain
fatty acids (>20 carbons), respectively.36,40,41
Subcutaneous casein injection is an established method
for induction of chronic systemic inflammation in mouse
models. This has been used in many studies of atheroscle-
rosis and hepatic steatosis.42e44 In comparison with other
sole cytokine or lipopolysaccharide (LPS) induced mouse
models, casein-injection induces a lower degree inflam-
matory stress characterized by increased multiple cyto-
kines (IL-1b, TNF-a and IL-6 etc.) and amyloid A (SAA, like
CRP in human) levels in serum, which is more likely to
mimic chronic systemic inflammatory state observed in
patients with inflammatory stress.45 We demonstrate that
inflammation induced by casein injection promotes hepatic
fatty acids synthesis mediated by SREBP1-ACCa/FAS and
disturbs fatty acids b-oxidation mediated by CPT1A, CROT
and HADHB in hepatic cells and livers of C57BL/6J mice.
This imbalance of fatty acids metabolism under inflamma-
tory stress exacerbates hepatic lipid accumulation and in-
duces endoplasmic reticulum (ER) stress and oxidative
stress, promoting progression of NAFLD.Effects of inflammation on cholesterol
accumulation in the liver
Dysregulation of both TG and FFA in NAFLD has been eluci-
dated in many studies, while the role of cholesterol in NAFLDused tobeneglected. Recent studies have indicated that liver
cholesterol accumulation is more toxic than TG andmay be a
trigger for progression of NAFLD. Studies have demonstrated
that free cholesterol levels are increased in the livers of NASH
patients.46 It has also been shown in experimental models
that free cholesterol loading, but not TG or FFA loading,
precipitates steatohepatitis.47 We have demonstrated that
chronic systemic inflammation induced by casein in mice
enhances cholesterol accumulation by increasing cholesterol
uptake via LDL receptor and cholesterol de novo synthesis via
HMGCoA-reductase in livers.42,48 In addition, inflammatory
stress disrupts PPAR-LXR-CYP7A1/ABCA1-mediated bile acid
synthesis and cholesterol efflux resulting in exacerbated
cholesterol accumulation in livers.49 Excess cholesterol
accumulation in cells can trigger ER stress, oxidative stress
and apoptosis, which aggravate NAFLD.50e52Inflammation and ectopic lipid accumulation in the
liver
NAFLD is associated with the increase in both obesity and
type 2 diabetes (T2DM). It has been demonstrated that
weight gain is an independent predictor of the development
of NAFLD, however there are still relatively high proportion
(w40%) of ChineseNAFLD patientswith normal BMI under the
ethnic-specific overweight and obesity criteria.53,54
Ectopic lipid deposition is defined as excess lipids
deposition in nonadipose tissues. In physiological condi-
tions, FFA delivered to adipose tissue is converted to TG for
storage during states of nutrient abundance. Therefore
white adipose tissue has a unique capacity to store large
amounts of excess lipid, while nonadipose tissues in which
FFA is utilized have a limited capacity for storage of
lipids.55,56 Adipose lipids also can be released into circula-
tion to form albumin/FFA complexes, which allow FFA
transport into nonadipose tissues, such as muscle, heart,
kidney and liver for beta-oxidation on demand. Insulin
regulates this process to maintain FFA homeostasis in bal-
ance. In pathophysiological state, ectopic lipid accumula-
tion in liver is the hepatic manifestation of the metabolic
syndrome, which is known to be associated with insulin
resistance and hyperlipidemia.57 Increasing lipogenesis in
nonadipose tissues plays a crucial role in ectopic lipid
deposition.18 In mammalian species, lipogenesis of cells is
under control of SREBP-1,2. SREBP-1 is selectively involved
in activation of genes in FFA metabolism by regulating the
expression of genes encoding rate-limiting enzymes
responsible for de novo lipogenesis, of which FAS and ACC
seem to be particularly important since the expression of
these genes is associated with the changes of FFA synthesis
rates. We have demonstrated that chronic systemic
inflammation up-regulates mRNA and protein expression of
SREBP1, ACCa and FAS in liver and muscle, while decreasing
the expression of these genes in adipose tissue.
FFA homeostasis of adipocytes is not only dependent on
lipogenesis but also lipolysis in adipose tissues. Numerous
studies have demonstrated that cytokines increase adipose
lipolysis, but the underlying mechanism is unclear. Both
adipose triglyceride lipase (ATGL) and hormone-sensitive
lipase (HSL) can initiate triglyceride (TG) degradation by
cleaving the first ester bond. Importantly, ATGL represents


















Figure 1 The role of inflammatory stress on hepatic lipid homeostasis. Inflammatory stress increases ATGL/HSL mediated
lipolysis in white adipose tissue. FFAs are released into the circulation to form albumin/FA complexes, which are transported into
hepatocytes by either passive transport or fatty acid transporting proteins (FATPs) including CD36. Inflammation up-regulates de
novo FFA synthesis expression and reduces FFA b-oxidation in liver.
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increased by insulin resistance is unique in its capacity to
break down the second ester bond, converting diglycerides
(DG) to monoglycerides in adipose tissue. We have shown
that inflammation increases both mRNA and protein
expression of ATGL and HSL in white adipose tissue, sug-
gesting that inflammation disrupts lipid metabolism by
increasing lipolysis in addition to an impaired lipogenesis in
adipose tissue. In addition, several studies have suggested
that cytokines may affect the stability of lipid droplets in
adipocytes by influencing the proteins that stabilize the
lipid droplet. TNF-a decreases lipid droplet protein peril-
ipin expression, presumably enhancing the ability of lipases
to access TG within the lipid droplets.59,60 TNF-a also de-
creases expression of a newly described lipid droplet pro-
tein fat-specific protein 27 (FSP27).61 These data suggest
that inflammation tissue-specifically ‘switches on’ lipo-
genesis in nonadipose tissues, especially in liver while
‘switches off’ lipogenesis and enhances lipolysis in adipose
tissue,58 promoting ectopic lipid accumulation in liver.
Inflammation and lipid redistribution in liver
Donnelly recently demonstrated that about 59% of liver
fatty acids in NAFLD patients is derived from the circula-
tion, 26% from de novo liver fatty acids synthesis and only
15% from the diet,31 suggesting that liver fatty acid comes
mainly from peripheral adipose tissue and abnormal fatty
acid transport to liver may be play an important role in the
development of NAFLD.
In insulin resistance, insulin does not suppress TG hydro-
lysis in adipose tissue; FFA are released into the circulation to
form albumin/FA complexes, which are transported into
hepatocytes by either passive transport or fatty acid trans-
porting proteins (FATPs) including CD36 (also called ‘fatty
acid translocase), plasma membrane fatty acid bindingprotein and caveolin. Genetic rodent models that alter
expression of lipid transport proteins provide evidence for
the role of ectopic lipid accumulation in the pathogenesis of
insulin resistance.62 Lipoprotein lipase (LpL) is a key enzyme
that hydrolyzes circulating triglyceride, permitting tissue
FFA uptake through FATPs. Hepatic specific overexpression
of LpL leads specifically to hepatic steatosis and hepatic in-
sulin resistance.63,64 Loss of hepatic fatty acid transport,
specifically through deletion of FATP265 or FATP5,66 protects
against the development of hepatic steatosis.
CD36, a type B scavenger receptor plays an important
role in hepatic FFA transport. CD36 is a transmembrane
glycoprotein, which is expressed in various cells associated
with energy metabolism, including adipocytes, pancreatic
beta cells, skeletal myocytes and hepatocytes. This multi-
functional receptor has been studied extensively with re-
gard to its role in facilitating the uptake of FFA and oxidised
low-density lipoproteins, which are involved in the aeti-
ology of such metabolic disorders as diabetes,67 athero-
sclerosis68 and NAFLD.69 Overexpression of CD36 aggravates
FFA and TG storage in human hepatoma cells and the livers
of C57BL/6J mice.70,71 In patients with NAFLD, CD36 up-
regulation is significantly associated with liver fat accu-
mulation.72 These findings suggest that hepatic CD36
expression is closely related to hepatic steatosis. Both
in vitro and in vivo, we have demonstrated that inflam-
matory stress enhances hepatic CD36 expression and in-
creases CD36 mediated- uptake of FFA, suggesting that
increased FFA uptake via CD36 is the one of mechanisms for
lipid redistribution to liver in addition to the enhanced
hepatic lipogenesis under inflammatory stress.
Conclusions
NAFLD is becoming a serious public health problem in the
world due to its effects on many metabolic disorders. It
110 Y. Chen et al.seems that inflammation and lipid disorder are two leading
causes for the progression of NAFLD. Inflammatory stress
initiates and promotes hepatic steatosis by modifying FFA
homeostasis including increasing hepatic FFA uptake, syn-
thase and reducing oxidation. Inflammation increases
ectopic lipid deposition and lipid redistribution from adi-
pose tissue to liver (Fig. 1). Excess hepatic cholesterol
accumulation under inflammatory stress can trigger ER
stress, oxidative stress and apoptosis, which may lead to
NASH-associated cirrhosis and end-stage liver disease.
However, there are many remaining questions, including
the deep mechanisms that control the progression from SS
to NASH that need to be answered. Since most of hepatic
lipids in NAFLD patients are derived from peripheral adi-
pose tissue and abnormal redistribution, more studies on
lipid homeostasis which links to organ crosstalk should be
investigated. Blocking abnormal lipid redistribution could
be a new therapeutic target for NAFLD prevention and
treatment.Conflict of interest statement
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